GlassScriptPhysician profile
Thomas L Lucas
NPI 1477746998
$9,637.34
in general payments reported to CMS, 2019-2025
47 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $1,126 · 2021: $1,932 · 2022: $2,746 · 2023: $1,124 · 2024: $1,203 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,671.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,120.65 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $836.49 | 2019-2024 | Airsupra, Farxiga, Evusheld |
| Glaxosmithkline, LLC. | $693.42 | 2019-2024 | Trelegy Ellipta, Arexvy, Bexsero |
| Novo Nordisk INC | $648.68 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Lilly USA, LLC | $593.50 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Janssen Pharmaceuticals, INC | $487.14 | 2021-2023 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.99 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $387.68 | 2021-2023 | |
| Horizon Therapeutics Plc | $383.90 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $368.53 | 2019-2023 | Trintellix |
| Pfizer INC. | $326.67 | 2019-2025 | |
| Esperion Therapeutics, INC. | $291.57 | 2020-2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $260.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $248.18 | 2019-2025 | |
| Amgen INC. | $243.77 | 2019-2025 | Krystexxa, Otezla, Repatha |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.